Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...

Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Jan 21 (Reuters) - Merck & Co unit MSD and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have ...

Merck's affordable Ebola vaccine initiatives, Abbott's profit challenges, U.S. vaccination policy changes under Health ...

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Taken together, Merck, Eli Lilly ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a Strong Buy.